Recce Pharmaceuticals Ltd
ASX:RCE.AX
0.515 (AUD) • At close September 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) AUD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 4.365 | 3.085 | 1.637 | 1.122 | 0.68 | 1.289 | 0.139 | 0.177 | 0.114 | 0.097 | 0 |
| Cost of Revenue
| 0.367 | 0.217 | 0.188 | 0.296 | 0.201 | 0.056 | 0.053 | 0.026 | 0.017 | 0.111 | 0.061 | 0.034 |
| Gross Profit
| -0.367 | 4.148 | 2.897 | 1.342 | 0.921 | 0.624 | 1.235 | 0.114 | 0.16 | 0.003 | 0.036 | -0.033 |
| Gross Profit Ratio
| 0 | 0.95 | 0.939 | 0.819 | 0.821 | 0.917 | 0.959 | 0.817 | 0.906 | 0.024 | 0.372 | -85.7 |
| Reseach & Development Expenses
| 0 | 7.167 | 6.224 | 5.557 | 1.985 | 0.416 | 0.372 | 0.999 | 0.142 | 0.054 | 0.009 | 0.009 |
| General & Administrative Expenses
| 0 | 4.113 | 2.373 | 6.813 | 1.587 | 1.596 | 1.337 | 1.54 | 4.187 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 1.118 | 0.994 | 0.696 | 0.19 | 1.767 | 1.531 | 1.619 | 0.617 | 0 | 0 | 0 |
| SG&A
| 21.684 | 17.108 | 13.963 | 15.069 | 5.207 | 3.363 | 2.867 | 3.159 | 4.805 | 0.41 | 0.227 | 0.202 |
| Other Expenses
| 0 | 4.282 | 1.532 | 1.593 | 0.974 | 0.571 | 1.189 | 0.111 | -0.198 | 0 | 0 | 0 |
| Operating Expenses
| 21.684 | 17.108 | 13.963 | 15.069 | 5.207 | 3.363 | 2.867 | 3.159 | 4.805 | 0.453 | 0.308 | 0.259 |
| Operating Income
| -22.051 | -17.326 | -14.15 | -15.364 | -5.408 | -3.419 | -2.921 | -3.185 | -4.821 | -0.45 | -0.272 | -0.292 |
| Operating Income Ratio
| 0 | -3.969 | -4.587 | -9.384 | -4.821 | -5.031 | -2.267 | -22.862 | -27.236 | -3.952 | -2.802 | -755.364 |
| Total Other Income Expenses Net
| -0.516 | -0.063 | 0.079 | 0.285 | 0.019 | -0.05 | -0.042 | 0.02 | -0.152 | -0 | -0 | -0 |
| Income Before Tax
| -22.568 | -17.389 | -14.071 | -15.079 | -5.388 | -3.469 | -2.963 | -3.165 | -4.973 | -0.45 | -0.272 | -0.292 |
| Income Before Tax Ratio
| 0 | -3.983 | -4.561 | -9.209 | -4.804 | -5.104 | -2.299 | -22.72 | -28.094 | -3.954 | -2.804 | -755.711 |
| Income Tax Expense
| -4.906 | -4.311 | -3.085 | -1.566 | -1.072 | -0.68 | -1.289 | -0.139 | -0.133 | 0 | 0 | 0 |
| Net Income
| -17.662 | -13.077 | -10.986 | -13.513 | -4.317 | -2.789 | -1.674 | -3.026 | -4.84 | -0.45 | -0.272 | -0.292 |
| Net Income Ratio
| 0 | -2.996 | -3.561 | -8.253 | -3.848 | -4.104 | -1.299 | -21.72 | -27.344 | -3.954 | -2.804 | -755.711 |
| EPS
| -0.1 | -0.074 | -0.063 | -0.086 | -0.034 | -0.029 | -0.02 | -0.039 | -0.085 | -0.014 | 0 | 0 |
| EPS Diluted
| -0.1 | -0.074 | -0.063 | -0.086 | -0.034 | -0.029 | -0.02 | -0.039 | -0.085 | -0.013 | 0 | 0 |
| EBITDA
| -21.684 | -17.108 | -13.963 | -15.069 | -5.207 | -3.363 | -2.867 | -3.159 | -4.805 | -0.44 | -0.264 | -0.287 |
| EBITDA Ratio
| 0 | -3.919 | -4.526 | -9.203 | -4.642 | -4.948 | -2.225 | -22.679 | -27.142 | -3.868 | -2.716 | -740.442 |